As 2025 draws to a close, animal nutrition companies are laying the groundwork for the year ahead to support their customers in navigating the ongoing volatility that has defined global agrifood markets in recent months. Huvepharma, a company celebrating 25 years as a fast-growing provider of animal health and nutritional solutions, is no exception.
"The industry faces increasing uncertainty from geopolitical tensions and global conflicts, which we have seen disrupt supply chains and market stability. It is vital that businesses actively diversify sourcing and strengthen regional operations to ensure continuity," Veerle Hautekiet, Global Marketing Director at Huvepharma, told Expana.
"We are also seeing markets shift toward local solutions, especially in emerging regions. To support this, Huvepharma is building strong local teams and capabilities to stay close to customers and adapt quickly."
According to Hautekiet, adapting to today's global trading environment requires a proactive approach as businesses face ongoing uncertainty and increasingly complex local regulatory requirements, which demand flexibility and compliance expertise.
"To maintain stability, we rely on our vertical integration, which gives us control over critical processes. Our manufacturing footprint with major facilities in the EU (Bulgaria) and in the US secures supply chain resilience so that we can deliver consistent quality and service, even in challenging and ever-changing trading conditions," Hautekiet said.
"We will keep driving organic growth by strengthening our core business and expanding our product portfolio to deliver holistic solutions. We also aim to extend existing products into new species such as aqua, and we will extend our presence in cattle, leveraging proven formulations to serve a broader range of customers. In parallel, we are investing in the production and development of new livestock vaccines. This will result in a new vaccine product line to roll out in the coming years," Huvepharma's Global Marketing Director added.
"Our aim is to provide an extensive portfolio of products and services that meet the changing needs of producers while also listening to the demands of the market. We have plans to extend our product and services portfolio for livestock, with the overarching vision to be a preferred partner to optimize health, welfare and productivity for all livestock producers. Our company continues to thrive on our traditional heritage of fermentation and manufacturing expertise, with planned investments in our vaccine plant a key focus moving forward," Hautekiet went on to say.
Moving forward, Huvepharma will be focused on entering and supporting growth in emerging markets where demand for animal health solutions is increasing rapidly.
"Latin America is a key focus due to its large and well-established livestock industry, offering strong potential for our portfolio. Asia represents another major opportunity, driven by rapid economic growth and increasing demand for animal health solutions. Africa is emerging as a high-potential region, with a huge population and significant unmet needs in animal health, making it an important area for long-term investment," she commented.
"By combining continued geographic presence in emerging markets, growing market shares in the more mature EU and US markets and adding new product lines, we are optimistic and confident to continue our historic growth path of year-to-year double digit growth."
Since the Bulgarian Lev has been linked to the euro at a fixed exchange rate for a number of years, Hautekiet also confirmed that there will be no material impact of Bulgaria's upcoming adoption of the euro in January 2026 on its business other than to facilitate Huvepharma's financial reporting needs.
Beyond market expansion, Huvepharma is on a journey to become carbon neutral by 2030. "We have already invested heavily in solar energy, including the opening of the EU's largest private battery energy storage plant earlier this year in Bulgaria," Hautekiet said. "In fact, our investments towards carbon neutrality have already reduced our overall carbon emissions by 30% since 2020. To reduce our reliance on fossil fuels, we're investing €300 million in converting our production processes to renewable energy including solar energy, battery energy storage systems, Greenburn(R) and electrifying our natural gas steam boilers."
As for company vision and values, Hautekiet said Huvepharma will continue to focus on quality, safety, trust and agility in 2026.
"We are committed to delivering products of the highest quality that are safe, reliable and worthy of our customers' confidence. We believe that strong, lasting partnerships with our customers create genuine value. By staying close to our customers, we gain the insights needed to anticipate their needs and respond swiftly as markets evolve."
"Trust is not given; it is earned through consistency, transparency, and a steadfast commitment to doing what we say we will do. At the same time, innovation fuels our progress. We constantly refine our processes, act on feedback and seek better ways to serve our partners and improve our operations."
"Finally, agility defines how we operate. As a highly integrated production company, we maintain direct control over our production processes, giving us the flexibility to adapt quickly and meet our customers' needs whenever and however they change."
"Together, these principles form the backbone of our culture and guide our actions at every level of the organization."
